<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468078</url>
  </required_header>
  <id_info>
    <org_study_id>FPCITKR001</org_study_id>
    <nct_id>NCT00468078</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients</brief_title>
  <acronym>FPCIT</acronym>
  <official_title>The Single Center, Phase III Clinical Trial to Evaluate the Efficacy and the Safety of [18F]FPCIT Positron Emission Tomography in Parkinson's Disease and Essential Tremor Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether F-18 FPCIT is effective and safe
      radiopharmaceutical for the objective diagnosis of Parkinson's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parkinson's disease is a common neurodegenerative disorder with loss of dopaminergic
      terminals in the striatum. Essential tremor is one of the conditions most commonly
      misdiagnosed as parkinsonism, and early clinical differentiation between these conditions can
      be difficult. F-18 FPCIT is a promising radiopharmaceutical for PET imaging to assess the
      dopamine transporter in the striatum.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>diagnostic sensitivity and specificity, and acute complication</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlation of specific striatal uptake to non specific uptake ratio of F-18 FPCIT and clinical sererity (H&amp;Y stage)</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parkinson's disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ET+Normal</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET/CT</intervention_name>
    <description>10min acquisition, 90min after injection of F-18 FPCIT</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Positron Emission Tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F-18 FPCIT</intervention_name>
    <description>5mCi, intravenous injection</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Parkinson's disease

          -  Male or female with age over 40 years

          -  Clinical diagnosis of Parkinson's disease

          -  Ability to give informed consent

        Essential tremor

          -  Male or female with age over 40 years

          -  Clinical diagnosis of Essential tremor

          -  Ability to give informed consent

        Healthy volunteers

          -  Male or female with age over 40 years

          -  No any symptoms or sign suggesting Parkinson's disease or essential tremor

          -  Ability to give informed consent

        Exclusion Criteria:

        Parkinson's disease and essential tremor

          -  Current pregnancy and breast feeding

          -  Current or past medical history of cardiac and neuropsychiatric disease

          -  Clinical evidence of dementia

          -  Inability to hold antiparkinsonian medication

          -  History of surgical therapy for tremor

          -  Severe or unstable medical or psychiatric condition

          -  Medication affecting CNS in last 6 months(e.g. CNS stimulants, sympathomimetics)

          -  Prior participation in other research protocol within 30 days

        Healthy volunteers

          -  Current pregnancy and breast feeding

          -  Current or past medical history of cardiac and neuropsychiatric disease

          -  Severe or unstable medical or psychiatric condition

          -  Drug abuse or medication affecting CNS (e.g. CNS stimulants, sympathomimetics) within
             6 months

          -  Prior participation in other research protocol within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Seung Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, Neumeyer J, Eidelberg D. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998 Sep;39(9):1521-30.</citation>
    <PMID>9744335</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2007</study_first_submitted>
  <study_first_submitted_qc>April 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2007</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Jae Seung Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Essential tremor</keyword>
  <keyword>F-18 FPCIT</keyword>
  <keyword>PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

